Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

INM
InMed Pharmaceuticals Inc. Common Shares
stock NASDAQ

Market Open
Jul 22, 2026 10:41:32 AM EDT
2.07USD+34.416%(+0.53)45,775,759
2.07Bid   2.08Ask   0.01Spread
Pre-market
Jul 22, 2026 9:29:50 AM EDT
2.15USD+39.610%(+0.61)3,275,697
After-hours
Jul 21, 2026 4:00:30 PM EDT
1.54USD+2.667%(+0.04)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 19, 2022
07:36AM EST  InMed Launches Cannabicitran, Expanding Its Rare Cannabinoid Portfolio For The Health And Wellness Sector   Benzinga
07:30AM EST  -- CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCV -- Expands the Companys rare cannabinoid product portfolio, which also includes cannabichromene (CBC) -- Strengthens leadership position in commercial scale production of high demand rare cannabinoids   GlobeNewswire Inc
Jan 5, 2022
07:30AM EST  InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today issued the following letter from President and CEO Eric A. Adams.   GlobeNewswire Inc
Dec 30, 2021
07:30AM EST  Registration Now Open For Tribe Publics Webinar   GlobeNewswire Inc
Dec 20, 2021
07:35AM EST  InMed Pharmaceuticals Announces Publication Of Peer-Reviewed Article On The Use Of CBN As A Potential Treatment For Glaucoma   Benzinga
07:30AM EST  InMed Pharmaceuticals Announces Publication of Peer-Reviewed   GlobeNewswire Inc
Dec 17, 2021
07:57PM EST  InMed Announces Results of 2021 Annual General Meeting   GlobeNewswire Inc
Nov 30, 2021
04:03PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021   Benzinga
Nov 29, 2021
06:21AM EST  HC Wainwright & Co. Initiates Coverage On InMed Pharmaceuticals with Buy Rating, Announces Price Target of $6   Benzinga
Nov 23, 2021
07:30AM EST  InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMeds management team is scheduled to participate in Cowens 4th Annual Cannabis Conference to be held virtually on November 29 December 1, 2021.   GlobeNewswire Inc
Nov 17, 2021
08:29AM EST  InMed Pharmaceuticals Provides Business Update   Benzinga
Nov 10, 2021
07:53AM EST  InMed Pharmaceuticals Q1 EPS $(0.25) Up From $(0.31) YoY   Benzinga
07:30AM EST  InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced financial results for the first quarter of fiscal year 2022 which ended September 30, 2021.   GlobeNewswire Inc
Nov 3, 2021
09:16AM EDT  InMed Pharmaceuticals Files PCT Patent Application For Treating Neurodegenerative Disease Using A Rare Cannabinoid   Benzinga
07:30AM EDT  -- Patent covers novel effects for neurodegenerative diseases -- Expands InMeds patent portfolio with incremental rare cannabinoid   GlobeNewswire Inc
Oct 19, 2021
06:03AM EDT  The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.50 A.M. EDT).   RTTNews
Oct 13, 2021
04:30PM EDT  InMed Pharmaceuticals Completes Acquisition of BayMedica Creating   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
07:32AM EDT  InMed Pharmaceuticals Announces Commencement Of Phase 2 Clinical Trial Investigating Cannabinol, A Rare Cannabinoid, In The Treatment Of Epidermolysis Bullosa   Benzinga
07:30AM EDT  InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical   GlobeNewswire Inc
Sep 29, 2021
09:47AM EDT  Hearing Edison Group Issues $24 Price Target On InMed Pharmaceuticals   Benzinga
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 24, 2021
07:39AM EDT  InMed Pharmaceuticals FY21 EPS $(1.52), Up From $(1.71) YoY   Benzinga
07:30AM EDT  InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.   GlobeNewswire Inc
04:01AM EDT  Earnings Scheduled For September 24, 2021   Benzinga
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 22, 2021
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 20, 2021
07:52AM EDT  InMed Pharmaceuticals Acquires BayMedica; Contract Valued At $4M, InMed To Issue 1.78M Shares To BayMedica's Equity And Convertible Debt Holders   Benzinga
Sep 18, 2021
12:16PM EDT  The Week In Cannabis: FDA, CDC, Delta-8 THC, WADA, Canopy, Sundial, Canada, LatAm And More   Benzinga
Sep 17, 2021
01:15PM EDT  InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, will report financial results for the fiscal year endedJune 30, 2021, onFriday, September 24, 2021.   GlobeNewswire Inc
07:34AM EDT  InMed Pharma To Present At Tribe Public's Webinar Presentation, Q&A Event 'Accelerating The Commercialization of Rare Cannabinoids' Sept. 21, 2021 At 8:30 a.m. EDT   Benzinga
07:30AM EDT  InMed Pharmaceuticals and BayMedica Participating in Tribe   GlobeNewswire Inc
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Sep 13, 2021
11:41AM EDT  InMed Pharmaceuticals To Acquire BayMedica, Rare Cannabinoid Manufacturer, For ~$3.66M   Benzinga
10:00AM EDT  InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids   Benzinga
07:46AM EDT  InMed Pharma Agrees To Acquire BayMedica; Transaction To Close In The Coming Weeks   RTTNews
07:45AM EDT  InMed Pharmaceuticals Signs Definitive Agreement To Acquire BayMedica For 1.78M InMed Common Shares   Benzinga
07:33AM EDT  Cannabis Industry Investor Presentations Now Available for On-Demand Viewing   PR Newswire
07:30AM EDT  -- Establishes leadership position in manufacturing and commercialization of rare cannabinoids -- Positions InMed within large and growing consumer health and wellness cannabinoid markets -- Transitions InMed into revenue generating company; acquires pipeline with numerous planned product launches   GlobeNewswire Inc
Sep 9, 2021
07:19PM EDT  InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announcedthat Eric. A. Adams, President and CEO of InMed will present at the H.C. Wainwright 23rd Annual Global Investment Conference which is being held virtually from September 13-15, 2021.   GlobeNewswire Inc
Sep 7, 2021
04:05PM EDT  InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com   PR Newswire
Sep 2, 2021
08:35AM EDT  Cannabis Industry Investor Conference: Company Executives Present September 8th   PR Newswire
Aug 25, 2021
01:28PM EDT  InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production Of Rare Cannabinoids At Pharmaceutical Levels   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 12, 2021
12:00PM EDT  InMed Pharmaceuticals to Present at the H.C. Wainwright   GlobeNewswire Inc
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 13, 2021
06:22AM EDT  InMed Pharma S-1 Earlier Showed Registration For ~8.07M Share Common Stock Offering Via Selling Shareholders   Benzinga
Jul 2, 2021
04:15PM EDT  InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that it has closed the previously announced private placement.   GlobeNewswire Inc
Jun 29, 2021
07:16AM EDT  InMed Pharma Signs Non-binding LoI To Acquire BayMedica   RTTNews
07:12AM EDT  InMed Pharmaceuticals Announces $12 Mln Private Placement Priced At-the-Market Under Nasdaq Rules   RTTNews
07:00AM EDT  InMed Pharmaceuticals Announces $12 Million Private   GlobeNewswire Inc
07:00AM EDT  InMed Pharmaceuticals Signs Non-binding Letter of Intent to   GlobeNewswire Inc
Jun 28, 2021
08:35AM EDT  Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com.   GlobeNewswire Inc
07:25AM EDT  InMed set to Become Major Player in Manufacturing of Rare Cannabinoids   Benzinga
Jun 22, 2021
12:29PM EDT  InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announcedthat Eric. A. Adams, President and CEO of InMed will present live at LifeSciencesInvestorForum.com on June 24th.   GlobeNewswire Inc
Jun 21, 2021
08:35AM EDT  Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.   GlobeNewswire Inc
Jun 17, 2021
11:18AM EDT  Shares of InMed Pharmaceuticals Inc. (INM) are gaining over 5% on Thursday morning after the clinical-stage company developing cannabinoid-based pharmaceutical drug candidates announced that its continued optimization of IntegraSyn has increased the cannabinoid yield to a level of 5 g/L.   RTTNews
07:30AM EDT  -- 5g/L cannabinoid yield significantly exceeds reported industry yields -- Significantly reduces the overall cost of rare cannabinoid manufacturing -- Continued advancement to GMP-ready large-scale batch production   GlobeNewswire Inc
Jun 9, 2021
11:30AM EDT  InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference   GlobeNewswire Inc
May 21, 2021
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 18, 2021
07:44AM EDT  The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO   Benzinga
May 13, 2021
07:36AM EDT  InMed Pharmaceuticals Q3 EPS $(0.41) Down From $(0.39) YoY   Benzinga
07:30AM EDT  InMed Pharmaceuticals Inc. (InMed or the Company) (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (CBN), today reported financial results for the third quarter of fiscal year 2021 (3Q21) which ended March 31, 2021.   GlobeNewswire Inc
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 6, 2021
07:30AM EDT  InMed Pharmaceuticals Inc. (InMed or the Company) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (CBN), will report financial results on Thursday, May 13, 2021 for the third quarter of fiscal year 2021 ending March 31, 2021.   GlobeNewswire Inc
May 4, 2021
07:30AM EDT  InMed to Present at Canaccord Genuitys 5th   GlobeNewswire Inc
Apr 28, 2021
07:58AM EDT  InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 Cream in a Phase 2 Trial for Epidermolysis Bullosa   Benzinga
07:30AM EDT  -- Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream -- Additional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks. -- Anticipated study on track to begin in 3Q 2021   GlobeNewswire Inc
Apr 27, 2021
07:30AM EDT  InMed Pharmaceuticals Announces Voluntary Delisting from TSX   GlobeNewswire Inc
Apr 26, 2021
07:30AM EDT  InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with   GlobeNewswire Inc
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
10:18AM EDT  Stocks That Hit 52-Week Lows On Monday   Benzinga
Mar 3, 2021
06:00PM EST  InMed to Present at Virtual Conferences in March 2021   GlobeNewswire Inc
Feb 16, 2021
11:13AM EST  Roth Capital Maintains Buy on InMed Pharmaceuticals, Lowers Price Target to $11.5   Benzinga
07:31AM EST  InMed Announces Closing of US$4.5 Million Private Placement   PR Newswire
Feb 11, 2021
08:19AM EST  InMed Pharmaceuticals Q2 Loss/shr Narrows To $0.37 From $0.48 Last Year   RTTNews
07:45AM EST  InMed Pharma Q2 Loss Per Share $0.37 Vs Loss $0.48 Last Year   RTTNews
07:31AM EST  InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results   PR Newswire
03:51AM EST  Earnings Scheduled For February 11, 2021   Benzinga
Feb 9, 2021
08:39AM EST  How The Major Indexes On OTC Markets Performed In 2020   Benzinga
Feb 5, 2021
09:01PM EST  InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results   PR Newswire
12:15PM EST  InMed Pharmaceuticals Stock Drops After It Presses Capital Raise Button   Benzinga
09:35AM EST  InMed Announces US$4.5 Million Private Placement   PR Newswire
Jan 19, 2021
02:00PM EST  InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived   PR Newswire
Jan 8, 2021
07:35AM EST  InMed Announces Results Of Second Phase 1 Clinical Trial Of INM-755 CBN Cream In Healthy Subjects   RTTNews
07:31AM EST  InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream   PR Newswire
Jan 5, 2021
04:53PM EST  InMed to Participate at Virtual Conferences in January 2021   PR Newswire
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 3, 2020
07:33AM EST  InMed Secures Exclusive, Worldwide License From EyeCRO LLC   RTTNews
07:31AM EST  InMed Licenses MiDROPS(r) Delivery Technology from EyeCRO for the Delivery of   PR Newswire
Nov 25, 2020
07:36AM EST  InMed Announces Results Of Initial Phase 1 Clinical Trial Of INM-755 CBN Cream In Healthy Subjects   RTTNews
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
07:31AM EST  InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream   PR Newswire
Nov 24, 2020
08:00PM EST  InMed Announces Election of Directors   PR Newswire
Nov 18, 2020
07:34AM EST  InMed Pharma, BayMedica To Collaborate To Manufacture, Test Novel Cannabinoid Therapeutics   RTTNews
07:31AM EST  InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing   PR Newswire
Nov 16, 2020
11:43AM EST  InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering   PR Newswire
Nov 13, 2020
02:38PM EST  Earnings Update: Village Farms With Pure Sunfarms, InMed Pharmaceuticals, THC BioMed Release Financial Results   Benzinga
07:33AM EST  InMed Q1 Net Loss C$2.1 Mln Or C$0.41/Shr Vs Net Loss C$3.4 Mln Or C$0.65/Shr Last Year   RTTNews
07:30AM EST  InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results   PR Newswire
Nov 12, 2020
10:19AM EST  Mid-Morning Market Update: Markets Mixed; TransDigm Earnings Top Estimates   Benzinga
09:11AM EST  InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC